amivantamab-vmjw – Talk Bio

Actionable Insights Powered by AI

Johnson & Johnson’s Rybrevant-Lazcluze Combination Shows Superior Survival Trend Over AstraZeneca’s Tagrisso in EGFR-Mutated Lung Cancer

8 months ago talkbio0Tagged amivantamab-vmjw, Chemotherapy-free, Clinical Research, EGFR-mutated lung cancer, Lazcluze, lazertinib, MARIPOSA, Non-Small Cell Lung Carcinoma, osimertinib, Rybrevant, Survival Analysis

Rybrevant (amivantamab-vmjw), Lazcluze (lazertinib), Tagrisso (osimertinib), EGFR-mutated lung cancer, Non-small cell lung cancer (NSCLC), MARIPOSA study, Survival analysis, Chemotherapy-free treatment

J&J Scores First-Line Approval for Rybrevant Combination in Lung Cancer with EGFR Exon 20 Mutations

1 year ago talkbio0Tagged amivantamab-vmjw, Approved, carboplatin-pemetrexed chemotherapy, Disease Progression, EGFR Exon 20, first-line, Insertion Mutation, Johnson and Johnson, Mortality Risk, Non-Small Cell Lung Carcinoma, Objective Response Rate, ORR, Progression-Free Survival, Reduced, Rybrevant, United States Food and Drug Administration

Johnson & Johnson, Rybrevant (amivantamab-vmjw), FDA Approval, First-Line Treatment, Non-Small Cell Lung Cancer (NSCLC), EGFR Exon 20 Insertion Mutations, Carboplatin-Pemetrexed Chemotherapy, Phase 3 PAPILLON Study, Reduced Disease Progression or Mortality Risk, Improved Objective Response Rate (ORR) and Progression-Free Survival (PFS)